July 2 (UPI) — The first dose of a drug developed by artificial intelligence has been delivered to its first patient.
Insilico Medicine, a biotechnology company based in Hong Kong, announced that human patients have begun receiving the drug INS018_055, an anti-fibrotic small molecule inhibitor. The company said the drug was discovered and designed with generative AI.
The drug has passed through two phases of trials before being administered to human patients.
“With demonstrated potential against both fibrosis and inflammation, INS018_055 could offer another option for patients worldwide,” Feng Ren, co-CEO and chief scientific officer of Insilico Medicine said in a statement.
Continue reading HERE
Source: https://www.upi.com/Science_News/2023/07/02/insilico-medicine-ai-developed-drug/4621688332959/
[Disclaimer]
